Anthony Hickey, PhD, conducts a multidisciplinary research program in the field of pulmonary drug and vaccine delivery. He is a Distinguished RTI Fellow and program director in inhaled therapeutics at the Center for Aerosol and Nanomaterials Engineering at the Research Triangle Institute; professor emeritus in the Division of Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy; and an adjunct professor of biomedical engineering at the UNC School of Medicine.
Hickey obtained his PhD (1984) and DSc (2003) in pharmaceutical sciences from Aston University in Birmingham, UK. Following postdoctoral positions at the University of Kentucky (1984-1988), he joined the faculty at the University of Illinois at Chicago (1988-1993) before coming to UNC, where he was a professor at the School from 1993 to 2010.
In 1990 Hickey received the AAPS Young Investigator Award in Pharmaceutics and Pharmaceutical Technology. He is a fellow of the UK Society of Biology (2000), the American Association of Pharmaceutical Scientists (2003), and the American Association for the Advancement of Science (2005). He has published numerous papers and chapters in the pharmaceutical and biomedical literature, one of which received the AAPS Meritorious Manuscript Award in 2001. He has edited five texts on pharmaceutical inhalation aerosols and coauthored others on pharmaceutical process engineering, particulate science, and pharmacocomplexity.
Hickey is the founder of two pharmaceutical companies — Cirrus Pharmaceuticals Inc. (1997) and Oriel Therapeutics Inc. (2001). He served as chief science officer of Oriel Therapeutics from 2002 to 2007, and the company was acquired by Sandoz in 2010. He has also served as president and CEO of Cirrus Pharmaceuticals since its founding. In addition, Hickey is a member of the Pharmaceutical Dosage Forms Expert Committee of the United States Pharmacopeia (2010–2015) and former chair of the Aerosols Expert Committee of the United States Pharmacopeia (2005-2010).